Most patients with completely resected stage III BRAF-mt cutaneous melanoma are candidates for any of the three different adjuvant treatments, whereas patients with completely resected stage III BRAF wild-type melanoma are only candidates for adjuvant treatment with pembrolizumab or nivolumab. Here, BRAF is linked to cutaneous melanoma.